Day Two - Thursday, August 1, 2024
8:00 am Check In & Coffee
8:25 am Chair’s Opening Remarks
Spotlighting Developments with Imaging and Aging Biology in Heart Failure
8:30 am Exploring the Potential of Cardiovascular Magnetic Resonance
Synopsis
- Exploring the capabilities of cardiovascular magnetic resonance for evaluation of patients with heart failure
- Examining the advantages of cardiovascular magnetic resonance for the assessment of cardiac structure and function
- Reviewing the biomarker potential of imaging tools for the assessment of myocardial fibrosis
9:00 am Using Proteomics to Target Aging Biology in Heart Failure
Synopsis
- Understanding the relevance of aging biology in heart failure pathophysiology
- Investigating distinct protein signatures of aging associated with heart failure
- Approaches to targeting aging biology for therapeutic development in heart failure
Innovations in Cardiovascular Precision Medicine
9:30 am Utilizing Population Genomics to Enhance Understanding, Prediction, & Management of Heart Failure
Synopsis
- Identifying new genetic loci linked to these diseases
- Creating polygenic risk scores to enhance disease prediction accuracy
- Carrying out Mendelian randomization experiments, including those that may have implications for potential drug targets
10:00 am Morning Break & Networking
10:30 am Reconceptualizing Gene Pathways in Heart Failure
Synopsis
- Exploring associations with signalling pathways and heart failure to accelerate early diagnosis
- Highlight progress in understanding of genetic architecture of heart failure
- Evaluating current capacities to deep mine existing knowledge to predict responses
11:00 am Probing How Cell Therapy can be Utilized in Heart Failure
Synopsis
- Delving into cell therapy using purified cardiomyocytes
- Exploring cardiac muscle regeneration through cell therapy
- Investigating categories of heart failure patients this would be applicable to
11:30 am Panel Discussion: Synergizing Gene and Cell Therapies in Cardiovascular Research: Integrating Precision Medicine Strategies
Synopsis
- How can the capabilities of gene and cell therapy be synergistically applied in cardiovascular research
- Reviewing the integration of precision medicine strategies in preclinical research
- From gene therapy to cell therapy to non-coding RNA which of these therapies hold the most promise
12:00 pm Lunch & Networking
1:00 pm Innovative Utilization of Real-World Evidence (RWE) in Early Heart Failure Drug Development
Synopsis
- Highlight the rationale and benefits of incorporating Real-World Evidence (RWE) early in drug development to understand disease burden and unmet needs, ensuring a strong foundation for clinical programs.
- Discuss how RWE supports the identification and validation of meaningful clinical endpoints, with case studies demonstrating its impact on endpoint selection and trial success.
- Explore the role of RWE in providing external control arms for early-phase clinical trials, showcasing examples of successful applications and their influence on trial design and outcomes.
Showcasing Novel Approaches with Small Molecules to Improve Contractility
1:30 pm Harnessing Small Molecules to Regulate Sarcomere Contractility
Synopsis
- Analyzing cardiac myosin manipulation
- Overcoming cardiac muscle function, muscle weakness and fatigue
- Evaluating categories of heart failure patients this would be applicable to
2:00 pm Targeting Cardiac Myosin Binding Protein C for Hypertrophic Cardiomyopathy & Heart Failure
Synopsis
- Investigating small molecules potential within heart failure
- Exploring the modulation of cardiac myosin binding protein C to improve cardiac function
- Discussing on going preclinical development
2:30 pm Panel Discussion: Dissecting Novel Biology from GLP-1RAs, to Small Molecules, to New Targets to Advance Progress in the Heart Failure Space
Synopsis
- Exploring the impact of incretins for cardiomyopathies
- Reviewing the potential of small molecules
- Delving into novel biology for cardiomyopathies
3:00 pm Delving to Non-Coding RNA Pathways as a New Frontier in Addressing Cardiac Diseases
Synopsis
- Understanding the regulatory importance of ncRNAs for cardiac cellular processes
- Engaging non-coding RNA pathway manipulation to reverse cellular pathology and restore normal function in cardiomyocytes
- Overcoming cardiac hypertrophy, fibrosis, impaired contractility and reduced vascularisation through an oligonucleotide-based inhibitor